Mar 15, 2019
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Mar 06, 2019
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
Feb 25, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN
Feb 21, 2019
Arterez Introduces a Novel, Triple-Compound Oral Therapy and Diagnostic Panels Targeting The Multi-Factorial 'Root-Causes' of Cardiovascular Disease - Not Cholesterol - in Human Studies
Feb 15, 2019
Statement from ABC President John M. Fontaine, MD, on the 2018 ACC/AHA Guideline on Management of Blood Cholesterol
Jan 29, 2019
Cardiovascular Disease Deaths May Double In U.S. By 2040 If New Treatment Innovations Are Not Discovered, Utilized
Jan 24, 2019
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Dec 11, 2018
Statin Markets: Worldwide Analysis & Outlook, 2019-2023 - Rising Prevalence of Hypercholesterolemia
Nov 26, 2018
CannaLean Develops New Cannabidiol & Chitosan Formulation to Safely Lower Cholesterol and Triglyceride Levels; A Stain Alternative With Fewer Risks
Nov 20, 2018
JACC: Cardiovascular Interventions Publishes Peer Reviewed Article on Neovasc Reducer(TM) Patient Case
Nov 13, 2018
Global Genomics Group (G3) Presents Data for the First Time on the Exact Size of Lipoprotein (a) Particles that Cause Plaque Buildup in Coronary Arteries from its GLOBAL Clinical Study Platform
Nov 12, 2018
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Nov 09, 2018
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH
Nov 05, 2018
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Oct 26, 2018
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Oct 24, 2018
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
Oct 02, 2018
Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health
Sep 18, 2018
NIH Funds Hingez Therapeutics to Develop New Cholesterol Pill
Sep 13, 2018
Hyperlipidemia Drugs Market Worth $22.6 Billion by 2022 | CAGR: 2.3%: Grand View Research, Inc.
Aug 21, 2018
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018